arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

MYRIAD GENETICS INC

MYGN
$3.25 ▲ +0.07 (+2.36%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
19 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

MYRIAD GENETICS INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $300.9M
Dividend Yield
Revenue Growth -1.6%
Op. Margin -47.0%
ROIC -73.5%
FCF / Share $0.02
Trailing P/E
Price / Book 0.8x
FCF Yield 0.6%
Debt / Equity 0.33
info Valuation on last close. End-of-day price, Aug 7, 2026.

19-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$824.50M
↓ -1.6%
Net Income Profit after all expenses
$-365.90M
↓ -187.4%
Operating Margin Operating profit as % of sales
-47.0%
↓ -218.5% 5th
FCF / Share Free cash flow per share
$0.02
↑ +120.2%
Long-Term Debt Long-term obligations
$119.90M
↑ +202.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
12
Returns
9
Financial Health
40
Cash Quality
22

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 19 years · 72 quarters